Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
June 03, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
May 17, 2021 08:05 ET
|
Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
May 13, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
May 10, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET CHARLESTON, S.C., May 10, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the...
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
May 06, 2021 08:05 ET
|
Aeterna Zentaris Inc
–In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
May 05, 2021 16:35 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
May 05, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets – Pivotal Phase 3 DETECT (Study P02)...
Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
May 03, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology CHARLESTON, S.C., May 03, 2021 (GLOBE...
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
April 28, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Company executing on growth strategy to build-out pipeline of development assets – Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q2 2021 ...